Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept Therapeutics’ CORT lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome, has been witnessing strong demand. The majority of the company’s top line is currently being driven by Korlym sales.
Korlym recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year. The company has also been expanding its efforts to identify and treat patients with Cushing’s syndrome, providing a potential runway for continued Korlym demand.
Reflecting growing momentum with Korlym and other business activities, management raised its full-year 2026 revenue guidance to $1.10-$1.20 billion, up from the earlier expectation of $950 million to $1.05 billion in 2026.
Korlym is likely to remain an important contributor to Corcept’s top-line growth through the remainder of 2026, supported by increasing demand for the treatment of Cushing’s syndrome and continued growth in prescriptions.
However, Corcept’s heavy reliance on Korlym for revenue growth remains a concern. Korlym sales were previously impacted by insufficient capacity at a specialty pharmacy vendor. Although sales have since regained momentum, Corcept continues to diversify its revenue base beyond Korlym to reduce its dependence on the drug.
CORT Eyes Lifyorli to Reduce Korlym Dependence
In March 2026, the FDA approved Lifyorli (relacorilant), Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. The approval of Lifyorli should help Corcept diversify its revenue base.
Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial availability. Though still in the early stages, Lifyorli should help reduce CORT’s heavy dependence on Korlym over time.
Relacorilant, in combination with other anticancer therapies, is also being studied for treating other cancer indications.
The phase II BELLA study (part A) is evaluating relacorilant plus nab-paclitaxel and Roche’s RHHBY Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer.
The BELLA study is designed to understand whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY’s Avastin — offers patients an additional treatment option or not.
The company is also evaluating relacorilant plus Pfizer’s PFE Xtandi (enzalutamide) in patients with early-stage prostate cancer. A phase II study is being conducted in collaboration with the University of Chicago.
Xtandi, which is approved for different stages of prostate cancer, has been one of Pfizer’s key revenue drivers.
Corcept is also developing relacorilant for treating Cushing's syndrome. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026.
CORT's Price Performance, Valuation and Estimates
Year to date, shares of Corcept have skyrocketed 218.5% against the industry’s decrease of 1.3%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Corcept is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 15.79, lower than 20.81 for the industry. The stock is, however, trading above its five-year mean of 7.42.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased from 58 cents to $2.02 over the past 60 days. During the same time frame, EPS estimates for 2027 have increased from $2.27 to $3.44.
Image Source: Zacks Investment Research
CORT’s Zacks Rank
Corcept currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpCorcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
